Novimmune Announces Presentations at 2015 American College of Rheumatology (ACR) Annual Meeting
Four Abstracts to Be Presented on NI-0501 for Treatment of Hemophagocytic Lymphohistiocytosis (HLH); Poster on NI-0101 for Rheumatoid Arthritis
(firmenpresse) - GENEVA, SWITZERLAND -- (Marketwired) -- 11/02/15 -- Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders and cancer, today announced plans for several presentations at the upcoming 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, California on November 6-11. The Company will present four abstracts on Novimmune's NI-0501, which targets interferon-gamma IFN? and is the first treatment developed specifically for Hemophagocytic Lymphohistiocytosis (HLH). The secondary form of HLH can be associated with inflammatory/autoimmune conditions. Novimmune is also presenting a poster on NI-0101, which targets Toll-like receptor 4.
"Discovering a safe and effective treatment for Hemophagocytic Lymphohistiocytosis, or HLH, is a core focus for us at Novimmune, so we are proud that four abstracts will be presented at ACR relating to our new drug, NI-0501, the first treatment specifically developed for HLH," said Novimmune Chief Executive Officer Jack Barbut. "We currently are testing NI-0501 as a first-line treatment for HLH at five investigational sites in the US and 14 sites in five European countries. In addition, a poster at ACR relates to translational data and phase 1 study results for NI-0101, our treatment for Rheumatoid Arthritis. We remain committed to further developing new and existing therapies to provide treatment options for patients dealing with devastating diseases like HLH and painful, debilitating autoimmune and inflammatory diseases."
Oral and poster abstract presentations on hemophagocytic lymphohistiocytosis (HLH) are as follows:
Cristina de Min(1), Vanessa Buatois(1), Laurence Chatel(1), Laura Cons(2), Francoise Richard(3), Claudia Bracaglia(4), Fabrizio De Benedetti Sr.(5), Marie Kosco-Vilbois(1) and Walter Ferlin(1), (1)Novimmune S.A., Geneva, Switzerland, (2)Novimmune S.A., Plan-Les-Ouates, Geneva, Switzerland, (3)Novimmune SA, Geneva, Switzerland, (4)Pediatric Medicine, Division of Rheumatology, Rome, Italy, (5)Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Tuesday, November 10, 2015
ACR Plenary Session III: Discovery 2015
ACR Plenary Session
: 11:00AM-12:30PM
Claudia Bracaglia(1), Giusi Prencipe(1), Antonio Gatto(2), Manuela Pardeo(1), Geneviève Lapeyre(3), Luigi Raganelli(1), Emiliano Marasco(2), Antonella Insalaco(2), Walter Ferlin(3), Robert Nelson(3), Cristina de Min(3) and Fabrizio De Benedetti Sr.(1), (1)Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, (2)Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, (3)Novimmune S.A., Geneva, Switzerland.
Tuesday, November 10, 2015
: Pediatric Rheumatology-Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions
ACR Poster Session C
: 9:00AM-11:00AM
Claudia Bracaglia(1), Denise Pires Marafon(2), Ivan Caiello(1), Kathy De Graaf(3), Florence Guilhot(4), Walter Ferlin(4), Sergio Davì(5), Grant Schulert(6), Angelo Ravelli(5), Alexei A. Grom(7), Robert Nelson(4), Cristina de Min(4) and Fabrizio De Benedetti Sr.(1), (1)Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, (2)Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, (3)Novimmune S.A., Geneva, Switzerland, (4)Novimmune S.A., Geneva, Switzerland, (5)Istituto Giannina Gaslini and University of Genova, Genova, Italy, (6)Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, (7)Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Tuesday, November 10, 2015
: Pediatric Rheumatology-Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions
ACR Concurrent Abstract Session
: 2:30PM- 4:00PM
Cristina de Min(1), Philippe Jacqmin(2), Christian Laveille(3), Robert Nelson(1), Florence Guilhot(1), Maureen Deehan(1), Marie Kosco-Vilbois(1), Walter Ferlin(1) and Genevieve Lapeyre(1), (1)Novimmune S.A., Geneva, Switzerland, (2)SGS Exprimo, Mechelen, Belgium, (3)SGS Exprimo NV, Mechelen, Belgium
Tuesday, November 10, 2015
: Pediatric Rheumatology-Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases
ACR Concurrent Abstract Session
: 2:30PM- 4:00PM
Emmanuel Monnet(1), Limin Shang(1), Geneviève Lapeyre(1), Kathy De Graaf(2), Eric Hatterer(1), Gaelle Wambiekele(1), Walter Ferlin(1), Philippe Jacqmin(3), Cem Gabay(4), Jeremy Sokolove(5), Simon Jones(6), Ernest H. Choy(7), Iain B. McInnes(8), Marie Kosco-Vilbois(1) and Cristina de Min(1), (1)Novimmune S.A., Geneva, Switzerland, (2)Novimmune S.A., Geneva, Switzerland, (3)SGS Exprimo, Mechelen, Belgium, (4)Rheumatology, Geneva University Hospital, Geneva, Switzerland, (5)Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, (6)Cardiff Institute of Infection & Immunity, Cardiff, United Kingdom, (7)Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, (8)Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Monday, November 9, 2015
: Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy Poster II
ACR Poster Session B
: 9:00AM-11:00AM
The American College of Rheumatology (ACR) is an ethically-driven, professional membership organization committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty. Founded in 1934, ACR is a not-for-profit, global medical society that serves over 9,500 physicians, health professionals and scientists worldwide.
HLH is a severe immune system disorder caused by an overactive and poorly controlled T cell function that triggers aberrant activation of the immune system. The disease typically arises in pediatric patients and is lethal if untreated. Even with the current best available care, HLH has a high rate of mortality.
Novimmune is currently testing a new drug, NI-0501, as a first-line and second-line treatment for HLH. The drug is the first treatment specifically developed for HLH. NI-0501 is a fully human monoclonal antibody that neutralizes interferon gamma, a cell-signaling protein believed to play a pivotal role in the development of HLH. In the ongoing phase II study, NI-0501 was initially administered to patients showing unsatisfactory response or intolerance to conventional therapies including chemotherapy, immune-suppressive medicines, and immune-depleting drugs. The recently approved amendment to the protocol allows NI-0501 to be administered to patients as a first-line treatment before any other intervention.
The study is currently underway at five investigational sites in the US and 14 sites in five European countries.
Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva. More information is available on the company website at .
Jack Barbut
+41 22 839 71 41
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 431110
Anzahl Zeichen: 0
contact information:
Town:
GENEVA, SWITZERLAND
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 183 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novimmune Announces Presentations at 2015 American College of Rheumatology (ACR) Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Novimmune SA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
